Lilly acquires Ventyx Biosciences

Lilly agreed to acquire Ventyx Biosciences. Reported deal value: $1B. Status: Pending. Sector: Biotechnology. Target headquarters context: San Diego, California, United States.

This page summarizes publicly available information about the transaction as of 2026-01-07. Figures and status may change as filings and press coverage update.

Get 3 Free Stock Ebooks Ventyx Biosciences stock jumped 62 .5% in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion The potential deal would value Ventyx at approximately double its Tuesday market cap of just over $500 million, with an announcement possible soon Ventyx develops oral therapies for inflammatory diseases like Crohn disease and rheumatoid arthritis, with one candidate in mid-stage trials for obesity-related cardiovascular disease The acquisition would expand Eli Lilly portfolio in autoimmune diseases and obesity...